Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{187271,
        author = {Pranjal shrichand Pawar and Vaishnavi Raju Bawne and Shankar Bhagawan khokle and Trupti Amod Raut and Avinash S. Jiddewar},
        title = {A Review On Naproxen - An Anti-inflammatory Agent - A complete pharmacokinetics, pharmacodynamics and comparative study of naproxen sodium tablet},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {6},
        pages = {7034-7039},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=187271},
        abstract = {steroidal Anti-inflammatory Drugs (NSAIDs) are the main therapeutic alternatives in treating pain and inflammation among various populations. However, they are linked with some adverse reactions and drug interactions. This review aims to summarize the naproxen mechanism of action, pharmacokinetic and pharmacodynamic with comparative study of naproxen sodium tablet and place it in the therapeutic strategy. Naproxen is a reversible inhibitor of the pro-inflammatory enzyme cyclooxygenase (COX) used in clinical practice for control of pain of various origin, namely post-traumatic pain (distortion and sprain), post- operative pains (in traumatology, orthopedics, gynecology, maxillofacial surgery), gynecological pains (pain and discomfort at primary dysmenorrhea, after the introduction of an intrauterine coil, etc.), headache and toothache, prevention or treatment of migraine, spinal pains, extrarticular rheumatism.
The objective of the present study is to develop a pharmaceutically stable and robust formulation of Naproxen sodium tablets USP 220mg comparable with innovator. In the present study we are reducing the excipients there by we can reduce the cost of the dosage form. The tablets of Naproxen sodium USP 220mg were successfully prepared by using wet granulation technique. Several trial formulations i.e., from F1-F10 have been taken to optimize and develop a robust formulation. The tablets were evaluated for weight variation, hardness, thickness, friability, % drug content, disintegration time and in vitro drug release. Formulation F10 showed a drug release of 103.5% in 60mins which is faster than the innovator product. The stability studies, shown that the formulation F10, F11 and F12 were stable enough at 400°C / 75% RH for a period of 3 months. Therefore, it can be concluded that the formulation F10 (Naproxen sodium tablets USP220mg) is robust and stable},
        keywords = {Cyclooxygenase (COX), Gastrointestinal (GI), Non-steriodal anti-inflammatory drugs (NSAID), Over -the- counter (OTC), Polyvinylpyrrolidone K-30 (PVP K- 30), Relative humidity (RH), Rapid mixer granulator (RMG), United States pharmacopoeia (USP).},
        month = {November},
        }